Pharmacy Compounding
Executive Summary
FDA's Pharmacy Compounding Advisory Committee will meet Feb. 4-5 to discuss bulk drug substances for use in pharmacy compounding that lack a US Pharmacopoeia or National Formulary monograph and are not components of FDA-approved drugs. The meeting starts at 8:30 a.m. at the CDER Advisory Committee Conference Center